Hyperimmune intravenous immunoglobulin (hIVIG) added to standard of care, including remdesivir (Veklury), did not improve clinical outcomes among hospitalized patients with severe COVID-19, a randomized trial found. People given hIVIG had no better ...
from Google Alert - health https://bit.ly/3s3z6Kv
via IFTTT
0 comments:
Post a Comment